drugset / Trial / NCT01017939

A Drug-Drug Interaction Study of Abiraterone Acetate Plus Prednisone With Dextromethorphan and Theophylline in Patients With Metastatic Castration-Resistant Prostate Cancer

NCT01017939

Phase 1 Completed 34 enrolled Janssen Research & Development, LLC
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the effects of multiple doses of abiraterone acetate plus prednisone on the pharmacokinetics (study of what the body does to a drug) of single doses of dextromethorphan hydrobromide and theophylline in patients with castration resistant prostate cancer.

Timeline

Start
2010-01
Primary completion
2010-06
Completion
2012-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Abiraterone acetate Small molecule 1000 mg Oral
Subject Dextromethorphan Unknown 30 mg Oral
Subject Prednisone Other / unclassified 5 mg Oral
Subject Theophylline Small molecule 100 mg Oral

Indications